Lupus & antiphospholipid syndrome
Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients
Authors' conclusion
In this study we applied SLE-DAS to assess the efficacy of sc BLM, by analysing its over-time changes and by comparing its performance with SLEDAI-2k.
Study context
- Population
- SLE patients treated with sc belimumab, monocentric cohortM/F 5/81
- Participants
- 86 patients
- Outcome
- Efficacy of sc BLM assessed by SLE-DAS (with SLEDAI-2K and PGA); remission by SLE-DAS (SLEDAS ≤2.08 + PDN ≤5mg/daily) and DORIS definitions
- Follow-up
- T12 (12 months)
Methodological detailsmonocentric, real-life setting
- Monocentric
- Real-life setting
Main finding
As reported in the abstract
Remission according to SLE-DAS definition (SLEDAS ≤2.08 + PDN ≤5mg/daily)
60.4%
Remission according to DORIS definition
62.3%
Observational data: associations, not effects.
Further findings
Baseline SLEDAI-2k, median (IQR) · baseline (T0)
- Median SLEDAI-2k
- 6
- IQR
- 4
Baseline SLE-DAS, median (IQR) · baseline (T0)
- Median SLE-DAS
- 5.77
- IQR
- 4.33
Correlation of SLEDAI-2k and SLE-DAS at baseline · baseline (T0)
- R
- 0.719 (95% CI 0.586-0.815, p<0.0001)
Change in SLEDAI-2k and SLE-DAS over time · T1, maintained in subsequent time-points
- Significant reduction of SLEDAI-2k and SLE-DAS already at T1, maintained in subsequent time-points
- P < 0.0001
Agreement between SLE-DAS and DORIS remission definitions · T12
- Agreement
- 84%
- Cohen's kappa
- 0.6
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →